Review Article
A systemic review on recent outbreaks of Dengue and newer US FDA approved drug
Author(s): Mahendra Kumar Sahu*, Dushika Sahu and Ghata Mandavi
This review is an update of dengue recent outbreaks and newer US FDA approved drugs based on worldwide data. Dengue is a self-limited, universal viral infection transmitted among person to person by mosquitoes. Mostly cases are asymptomatic or mild and can be managed without complications. It is estimated that 390 million dengue virus infections are reported per year of which 96 million is observed clinically with many severe symptoms as per WHO and CDC. The pathophysiology of dengue fever (DENV) is not properly understood. Primary indication of disease includes capillary leak syndrome (plasma leakage due to dengue hemorrhagic fever specific dysfunction of endothelial cells), thrombocytopenia (seen in all type of DENV infection), hemorrhagic tendencies and leukopenia. Furthermore clinical dengue fever can be diagnosed by NS1 antigen capture test, NS1 antigen capture test, antibody tes.. Read More»
DOI:
10.37532/0975-5071.2023.15.01
